Fatty Acid Oxidation Disorders 2
The Fatty Acid Oxidation Disorders 2 session will be discussing MADD, SCADD, SCHAD, CUD, SCOT, BKT.
Nicola Longo, MD, PhD
Professor of Pediatrics and Chief, Division of Medical Genetics
University of Utah
Nichola Longo, faculty for this educational event, is on the Advisory Board for Alnylam, Amicus Therapeutics, BridgeBio/CoA Ther, Censa/PTC Therapeutics, Chiesi/Protalix, Genzyme/Sanofi, Hemoshear, Horizon Pharmaceuticals, Jaguar Gene Therapy, Leadiant Biosciences, Moderna, Nestle Pharmaceutical, Recordati, Reneo, Shire/Takeda and Ultragenix; provides Clinical Trial Support for Aeglea, Amicus Therapeutics, Audentes/Astellas, AvroBio, BioMarin, Censa/PTC Therapeutics, Chiesi/Protalix, Genzyme/Sanofi, Hemoshear, Homology, Horizon Pharmaceuticals, Moderna, Nestle Pharamceuticals, Pfizer, Reneo, Retrophin, Shire/Takeda, Stealth Therapeutics, Synlogic and Ultragenix; is a Data Safety and Monitoring Chair for ACI Clinical and on the Data Safety and Monitoring Board for CTI; and is a consultant for Synlogic.
Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed have been mitigated.
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this Other (Internet Live) activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
A general certificate of attendance will be available after the completion of the online evaluation. Claim only credit commensurate of your conference attendance.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance